Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Advanced Breast Cancer
Interventions: DRUG: CYH33|DRUG: Fulvestrant|DRUG: Letrozole|DRUG: Palbociclib
Sponsor: Haihe Biopharma Co., Ltd.